Cyclosporine A and COVID19 – The COQUIMA cohort

Cyclosporine A and COVID19 – The COQUIMA cohort

Bibliographic Details
Main Author:	Olga Sánchez-Pernaute
Format:	Article
Language:	English
Published:	Elsevier 2021-01-01
Series:	EClinicalMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537020304235

Similar Items

Cyclosporine A and COVID-19 – The COQUIMA cohort
by: Macé M. Schuurmans, et al.
Published: (2021-01-01)

Cyclosporine A and COVID19 – The COQUIMA cohort – Author's reply
by: Pablo Guisado-Vasco, et al.
Published: (2021-01-01)

Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?
by: Christian A. Devaux, et al.
Published: (2021-09-01)

Use of Cyclosporine Therapy in Dermatology During COVID-19 Pandemic
by: Y.S. Pathania
Published: (2022-07-01)

A phase I trial of cyclosporine for hospitalized patients with COVID-19
by: Emily A. Blumberg, et al.
Published: (2022-06-01)

Cyclosporine
by: Nahide Onsun
Published: (2022-04-01)

Cyclosporine
by: Russell, N, et al.
Published: (2008)

Structure of Cyclosporine and Its Metabolites: Total Synthesis of Cyclosporine Metabolites Formed by Oxidation at Positions 4 and 9 of Cyclosporine. Preparation of Leucine-4-cyclosporine, (?-Hydroxy)-N-methyl-leucine-9-cyclosporine and Leucine-4-(?-hydroxy)-N-methyl-leucine-9-cyclosporine
by: Roland M. Wenger, et al.
Published: (1992-07-01)

The cyclosporine syringe: A pragmatic approach for accurate calibration of cyclosporine dosing in children
by: Sandipan Dhar, et al.
Published: (2021-01-01)

Cyclosporine in cholinergic itch
by: Sumit Sehgal, et al.
Published: (2022-01-01)

Pretransplant assessment of cyclosporine level as a predictor of cyclosporine dose requirements after kidney transplantation
by: Sahier O El-Khashab, et al.
Published: (2019-01-01)

Cyclosporine in the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome: Retrospective Cohort Study
by: Sophia Zita, et al.
Published: (2023-07-01)

Effect of Fosfomycin on Cyclosporine Nephrotoxicity
by: Juan Antonio Ortega-Trejo, et al.
Published: (2020-10-01)

The controversial early history of cyclosporin
by: K Heusler, et al.
Published: (2001-06-01)

Development of the force field for cyclosporine A
by: Tsutomu Yamane, et al.
Published: (2022-12-01)

Cyclosporine Neoral: A Local Experience
by: Nampoory Mangalathillam, et al.
Published: (1999-01-01)

The role of cyclosporine A on the periodontal tissues
by: Mallappa Jayasheela, et al.
Published: (2013-01-01)

CYCLOSPORIN A IN THERAPY FOR JUVENILE ARTHRITIS
by: E S Fedorov, et al.
Published: (2010-06-01)

Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection
by: Marcella Ricardis May, et al.
Published: (2022-01-01)

Cyclosporine A in hospitalized COVID-19 pneumonia patients to prevent the development of interstitial lung disease: a pilot randomized clinical trial
by: Tatiana Cobo-Ibáñez, et al.
Published: (2024-02-01)

A Monocentric Retrospective Cohort of Patients with Severe Atopic Dermatitis Treated with Cyclosporine A in Daily Practice
by: Justine Daguzé, et al.
Published: (2017-05-01)

Efficacy and Safety of 0.1% Cyclosporine versus 2% Cyclosporine in the Treatment of Severe Vernal Keratoconjunctivitis in Children
by: Bourcier T, et al.
Published: (2022-10-01)

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
by: Periman LM, et al.
Published: (2020-12-01)

ABC of monitoring drug therapy. Cyclosporin.
by: Reynolds, D, et al.
Published: (1992)

OF THE APPLICATION OF THE CYCLOSPORINE GENERICS IN THE PEDIATRIC RHEUMATOLOGY
by: S.I. Valieva, et al.
Published: (2007-01-01)

OF THE APPLICATION OF THE CYCLOSPORINE GENERICS IN THE PEDIATRIC RHEUMATOLOGY
by: S.I. Valieva, et al.
Published: (2007-07-01)

Cyclosporine-induced childhood generalized hypertrichosis,
by: Karilena Fernandes Souza, et al.
Published: (2020-07-01)

Comparison of two commercial cyclosporin assays
by: Vučeljić Marina, et al.
Published: (2007-01-01)

Can we predict the response to cyclosporine?
by: J. Hinojosa del Val, et al.

Effect of Erythromycin on the Intestinal Transport of Cyclosporine
by: P Zakeri Milani,, et al.
Published: (2009-06-01)

Cyclosporine-induced multiple sebaceous hyperplasia
by: Yun-Wen Chiu, et al.
Published: (2017-03-01)

Nursing interventions in oral administration of Cyclosporine
by: Savić Maja
Published: (2023-01-01)

Assessment of the efficiency of cyclosporine use in psoriasis
by: Kruglova L.S., et al.
Published: (2017-09-01)

Absence of clinically relevant effect of caspofungin on cyclosporin pharmacokinetics
by: C Sanz-Rodriguez, et al.
Published: (2005-11-01)

Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
by: Shaveta Singla, et al.
Published: (2019-01-01)

Acute cyclosporine overdose: A systematic review
by: Ali Ershad, et al.
Published: (2023-04-01)

Current progress on clinical application of cyclosporine A
by: Yan-Ning Yang, et al.
Published: (2017-03-01)

Cyclosporine in dermatology results of a pilot study
by: Rahul Ray, et al.
Published: (2013-01-01)

Cyclosporine A nephropathy, its pathogenesis and management
by: Yusuf Erçin Sonmez
Published: (2021-12-01)

CYCLOSPORINE A IN RHEUMATOID ARTHRITIS: CURRENT DATA
by: Elena Lvovna Luchikhina
Published: (2009-09-01)